Benzisothiazoles and $\beta$-Adrenoceptors: Synthesis and Pharmacological lnvestigation of Novel Propanolamine and Oxypro-panolamine Derivatives in Isolated Rat Tissues

  • Morini Giovanni (University of Parma, School of Pharmacy, Pharmaceutical Department) ;
  • Poli Enzo (School of Medicine, Department of Human Anatomy, Pharmacology and Medico-Forensic Sciences, Section of Pharmacology) ;
  • Comini Mara (University of Parma, School of Pharmacy, Pharmaceutical Department) ;
  • Menozzi Alessandro (School of Medicine, Department of Human Anatomy, Pharmacology and Medico-Forensic Sciences, Section of Pharmacology) ;
  • Pozzoli Cristina (School of Medicine, Department of Human Anatomy, Pharmacology and Medico-Forensic Sciences, Section of Pharmacology)
  • Published : 2005.12.01

Abstract

In an attempt to examine the ability of benzisothiazole-based drugs to interact with $\beta$-adrenoceptors, a series of 1,2-benzisothiazole derivatives, which were substituted with various propanolamine or oxypropanolamine side chains in the 2 or 3 position, were synthesised and tested. The pharmacological activity of these compounds at the ,$\beta$-adrenoceptors was examined using isolated rat atria and small intestinal segments, which preferentially express the $\beta_{1}$- and $\beta_{3}$-adrenoceptor-mediated responses, respectively. None of these products showed any $\beta$-adrenoceptor agonistic activity. In contrast, the 2- and 3-substituted isopropyl, tert-butyl, benzyl, and piperonyl derivatives 2a-d and 3a-d elicited surmountable inhibition of the isoprena­line-induced chronotropic effects in the atria, suggesting competitive antagonism at the $\beta_{1}$­recognition site. The $pA_{2}$ values revealed tert-butyl 3b and the isopropyl substituted piperonyl derivatives 3a to be the most effective. Remarkably, many of the 2-substituted propanolamines were less active than the corresponding 3-substituted oxypropanolamines. With the exception of compound 3b, none of these drugs antagonised the muscle relaxant activity of isoprenaline in the intestine, suggesting no effect on the $\beta_{3}$-adrenoceptors. These results confirm the ability of the benzisothiazole ring to interact with the $\beta$-adrenoceptors, and demonstrate that 2-substitution with propanolamine or 3-substitution with oxypropanolamine groups yields compounds with preferential antagonistic activity at the cardiac $\beta_{1}$adrenoceptors. The degree of antagonism depends strongly on both the nature of the substituent and its position on the benzisothiazole ring.

Keywords

References

  1. Amoretti, L., Catellani, P. L., Impicciatore, M., and Cavaggioni, A., Biological properties of 1,2-benzisothiazole compounds. Local anaesthetic activity of amides and esters of 1,2- benzisothiazol-3-ylcarboxylic acid. Il Farmaco, 27, 855-865, (1972)
  2. Arch, J. R. S., The $\beta_{3}$-adrenergic system and $b_{3}$-adrenergic agonists. Rev. Endocr. Metab. Dis., 2, 385-393 (2001) https://doi.org/10.1023/A:1011852500209
  3. Barocelli, E., Chiavarini, M., Ballabeni, V., Mingiardi, M. R., Morini, G., Ronchini, R., and Impicciatore, M., Pharmacological properties of new 1,2-benzisothiazolyl oxypropanolamines on cardiac and tracheal $\beta$-receptors. Boll. Soc. It. Biol. Sperim., 68, 445-451 (1992)
  4. Benfield, P., Clissold, S. P., Brogden, R. N., Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs, 31, 376-429 (1986) https://doi.org/10.2165/00003495-198631050-00002
  5. Bertaccini, G., Coruzzi, C., Poli, E., and Adami, M., Pharmacology of the novel $H_{2}$ antagonist famotidine: in vitro studies. Agents Actions, 19, 180-187 (1986) https://doi.org/10.1007/BF01966204
  6. Blin, N., Camion, L., Magret, B., and Strosberg, A. D., Structural and conformational features determining selective signal transduction in the $\beta_{3}$-adrenergic receptor. Mol. Pharmacol., 44, 1094-1104 (1993)
  7. Candelore, M. R., Deng, L., Tota, L., Xiao-Ming, G., Amend, A., Liu, Y., Newbold, R., Cascieri, M. A., and Weber, A. E., Potent and selective human $\beta$-adrenergic receptor antagonists. J. Pharm. Exp. Ther., 290, 649-655 (1999)
  8. Coruzzi, G. and Poli, E., Changes in duodenal contractility induced by 'calcium antagonists' with different modes of action. Gen. Pharmacol., 18, 69-74 (1987) https://doi.org/10.1016/0306-3623(87)90172-8
  9. Ishibashi, T., Ikeda, K., Ishida, K., Yasui, J., Tojima, R., Nakamura, M., and Ohno, Y., Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Eur. J. Pharmacol., 303, 247- 251 (1996) https://doi.org/10.1016/0014-2999(96)00139-2
  10. Kaumann, A. J. and Molenaar, P., Differences between the third cardiac $\beta$-adrenoceptor and the colonic $\beta_{3}$-adrenoceptor in the rat. Br. J. Pharmacol., 118, 2085-2098 (1996) https://doi.org/10.1111/j.1476-5381.1996.tb15648.x
  11. Kenakin, T. P., Drug antagonism, in Kenakin, T. P. (Ed.), Pharmacologic analysis of drug-receptor interaction. Raven Press, New York, pp. 205-225 (1987)
  12. Kusayama, T., Oka, J., Yabana, H., Adaki-Akahane, and S., Nagao, T., Binding of a catechol derivative of denopamine (T.0509) and N-tert-butylnoradrenaline (Colterol) to $\beta_{1}$- and $\beta_{2}$-adrenoceptors. Biol. Pharm. Bull., 17, 1023-1027 (1994) https://doi.org/10.1248/bpb.17.1023
  13. Mingiardi, M. R., Maggiali, C. A., and Ronchini, F., 1,2- Benzisothiazole derivatives potentially active as $\beta$-blockers. Ateneo Parmense, Acta Nat., 19, 145-151 (1983)
  14. Molina, E., Zappia, L., Amoretti, L., and Catellani, P. L., Biological properties of 1,2-benzisothiazole compounds. Spasmolytic activity of benzisothiazol-3-ylcarboxyamides. Ateneo Parmense, Acta Bio-Med., 45, 183-189 (1974)
  15. Morini, G., Pozzoli, C., Adami, M., Poli, E., and Coruzzi, G., Synthesis of 1,2-benzisothiazole derivatives and investigation of their putative histaminergic activity. Il Farmaco, 54, 740- 746 (1999) https://doi.org/10.1016/S0014-827X(99)00093-2
  16. Morini, G., Pozzoli, C., Menozzi, A., Comini, M., and Poli, E., Synthesis of 1,2-benzisothiazolyloxypropanolamine derivatives and investigation of their activity at $\beta$-adrenoceptors. Il Farmaco, 60, 810-817 (2005) https://doi.org/10.1016/j.farmac.2005.07.008
  17. Mos, J., Van-Hest, A., Van Drimmelen, M., Herremans, A. H., and Olivier, B., The putative 5-HT$_{1A}$ receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT$_{1A}$ receptor agonist flesinoxan in pigeons. Eur. J. Pharmacol., 325, 145-153 (1997) https://doi.org/10.1016/S0014-2999(97)00131-3
  18. Roberts, S. J., Papaioannou, M., Evans, B. A., and Summers, R, J., Characterisation of $\beta$-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for $\beta_{1}$-, $\beta_{2}$-, and $\beta_{3}$-adrenoceptors in rat ileum. Br. J. Pharmacol., 127, 949- 961 (1999) https://doi.org/10.1038/sj.bjp.0702605
  19. Strosberg, A. D., Structure and function of the $b_{3}$-adrenergic receptor. Annu. Rev. Pharmacol. Toxicol., 37, 421-450 (1997) https://doi.org/10.1146/annurev.pharmtox.37.1.421
  20. Sum, F. W., Wong, V., Han, S., Largis, E., Mulvey, R., and Tillett, J., Cyclic amine sulfonamides as linkers in the design and synthesis of novel human $\beta_{3}$ adrenergic receptor agonists. Bioorg. Med. Chem. Lett., 13, 2191-2194 (2003) https://doi.org/10.1016/S0960-894X(03)00387-1
  21. Von Franche, A., Frickel, F. F., Gries, J., Lehman, H. D., Lenke, D., and Ohnsorge, U., New $\beta$-sympatholytic agents: synthesis and pharmacological activity of isomeric benzothiazole and benzoxazole derivatives. Arzneim. Forsch. Drug Res., 30, 1831-1835 (1980)
  22. Wadworth, A. N., Murdoch, D., and Brogden, R. N., Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs, 42, 468-510 (1991) https://doi.org/10.2165/00003495-199142030-00007